Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yimeng Chang

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Sensors (Basel, Switzerland)|September 28, 2023
OTE-SLAM: An Object Tracking Enhanced Visual SLAM System for Dynamic EnvironmentsYimeng Chang, Jun Hu, Shiyou Xu
Journal of Neuroinflammation|May 7, 2026
Hyperactive basolateral amygdala mediates comorbid anxiety in chronic rhinosinusitisXiaojun Zhang, Wensi Wu, Haomiao Zhao, et al.
Nature Medicine|June 8, 2019
Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patientsRyan J Sullivan, Omid Hamid, Rene Gonzalez, et al.
American Journal of Hematology|January 3, 2023
Targeting MCL-1 and BCL-2 with polatuzumab vedotin and venetoclax overcomes treatment resistance in R/R non-Hodgkin lymphoma: Results from preclinical models and a Phase Ib studyElisabeth A Lasater, Dhara N Amin, Rajat Bannerji, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Sensors (Basel, Switzerland)|September 28, 2023
OTE-SLAM: An Object Tracking Enhanced Visual SLAM System for Dynamic EnvironmentsYimeng Chang, Jun Hu, Shiyou Xu
Journal of Neuroinflammation|May 7, 2026
Hyperactive basolateral amygdala mediates comorbid anxiety in chronic rhinosinusitisXiaojun Zhang, Wensi Wu, Haomiao Zhao, et al.
Nature Medicine|June 8, 2019
Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patientsRyan J Sullivan, Omid Hamid, Rene Gonzalez, et al.
American Journal of Hematology|January 3, 2023
Targeting MCL-1 and BCL-2 with polatuzumab vedotin and venetoclax overcomes treatment resistance in R/R non-Hodgkin lymphoma: Results from preclinical models and a Phase Ib studyElisabeth A Lasater, Dhara N Amin, Rajat Bannerji, et al.
Pageof 1